BridgeBio Pharma (BBIO) News Today $33.79 -0.32 (-0.94%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Moss Adams Wealth Advisors LLC Makes New $208,000 Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Moss Adams Wealth Advisors LLC bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 7,577 shares of the company's stock, valued atJanuary 20 at 4:47 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest Up 12.7% in DecemberBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 19,300,000 shares, an increase of 12.7% from the December 15th total of 17,120,000 shares. Based on an average daily trading volume, of 1,940,000 shares, the days-to-cover ratio is currently 9.9 days. Currently, 13.1% of the shares of the stock are sold short.January 18 at 3:52 PM | marketbeat.comBridgeBio Pharma, Inc. (BBIO) Stock ForecastsJanuary 17 at 3:22 AM | ca.finance.yahoo.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6% - Time to Buy?BridgeBio Pharma (NASDAQ:BBIO) Trading Up 6.6% - Still a Buy?January 16, 2025 | marketbeat.comBridgeBio Pharma: Strong Market Entry and Promising Pipeline Support Buy RatingJanuary 15, 2025 | markets.businessinsider.comBridgeBio Pharma: Balancing Promising Launch Metrics and Future Uncertainties with a Hold RatingJanuary 15, 2025 | markets.businessinsider.comBridgeBio Pharma Is A Buy On Dips After Attruby's FDA ApprovalJanuary 15, 2025 | seekingalpha.comIs BridgeBio Pharma, Inc. (BBIO) Among Tuesday’s Top Gainers?January 15, 2025 | insidermonkey.comScotiabank Keeps Their Buy Rating on BridgeBio Pharma (BBIO)January 14, 2025 | markets.businessinsider.comOppenheimer Sticks to Its Hold Rating for BridgeBio Pharma (BBIO)January 14, 2025 | markets.businessinsider.comWhy BridgeBio Pharma (BBIO) Led the Monday Upsurge?January 14, 2025 | msn.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6% - Here's WhyBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 6.6% - Still a Buy?January 14, 2025 | marketbeat.comTraders Purchase High Volume of BridgeBio Pharma Call Options (NASDAQ:BBIO)January 14, 2025 | americanbankingnews.comBank of America Securities Keeps Their Buy Rating on BridgeBio Pharma (BBIO)January 14, 2025 | markets.businessinsider.comOptimistic Buy Recommendation for BridgeBio Pharma Amid Promising Developments and Competitive Market DynamicsJanuary 14, 2025 | markets.businessinsider.comBridgeBio announces commercial progress, pipeline updatesJanuary 13, 2025 | markets.businessinsider.comBridgeBio trades higher on pipeline progressJanuary 13, 2025 | in.investing.comBridgeBio Pharma in Strong Cash Position to Launch AttrubyJanuary 13, 2025 | marketwatch.comBridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume Increase - Time to Buy?BridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading Volume - Should You Buy?January 13, 2025 | marketbeat.comBridgeBio Pharma Target of Unusually High Options Trading (NASDAQ:BBIO)BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) was the target of some unusual options trading on Monday. Investors acquired 13,167 call options on the company. This represents an increase of approximately 210% compared to the typical volume of 4,241 call options.January 13, 2025 | marketbeat.comBridgeBio Announces Commercial Progress, Program Updates, and 2025 MilestonesJanuary 13, 2025 | globenewswire.comOptimistic Growth Projections and Financial Adjustments Justify Buy Rating for BridgeBio PharmaJanuary 10, 2025 | markets.businessinsider.comBridgeBio Pharma to Participate in the J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has been given a consensus rating of "Moderate Buy" by the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and twelve have assigned a buJanuary 6, 2025 | marketbeat.comIs This Biotech Stock With 150% Upside a Buy Now?December 30, 2024 | msn.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Purchased by Principal Financial Group Inc.Principal Financial Group Inc. boosted its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 1,145,123 shares of the company's stock after purchasing an additional 19,978 sharDecember 25, 2024 | marketbeat.comBridgeBio price target raised to $50 from $45 at Evercore ISIDecember 23, 2024 | markets.businessinsider.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Evercore ISI Analyst SaysEvercore ISI lifted their target price on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research report on Monday.December 23, 2024 | marketbeat.comGeode Capital Management LLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Geode Capital Management LLC grew its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,413,949 shares of the company's stock aftDecember 20, 2024 | marketbeat.comWellington Management Group LLP Trims Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Wellington Management Group LLP lowered its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 95.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 69,586 shares of the company's stock after selling 1,400,524 shares during the quarDecember 19, 2024 | marketbeat.comPiper Sandler Remains a Buy on BridgeBio Pharma (BBIO)December 18, 2024 | markets.businessinsider.comOptimistic Buy Rating for BridgeBio Pharma Due to Strong Launch and Strategic InitiativesDecember 18, 2024 | markets.businessinsider.comBridgeBio Pharma’s Growth Prospects Bolstered by Acoramidis Approval and Promising PipelineDecember 17, 2024 | markets.businessinsider.comHC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO)HC Wainwright reaffirmed a "buy" rating and issued a $49.00 price objective on shares of BridgeBio Pharma in a research note on Monday.December 16, 2024 | marketbeat.comBarclays PLC Boosts Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Barclays PLC raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 31.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 545,008 shares of the company's stock after acquiring an additional 131,743 shares during the period. BarclDecember 16, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) is Exome Asset Management LLC's 3rd Largest PositionExome Asset Management LLC grew its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 167.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 211,000 shares of the company's stock after acquiring an additiDecember 14, 2024 | marketbeat.comBridgeBio Pharma Announces CHMP's Positive Recommendation Of Acoramidis - Quick FactsDecember 13, 2024 | markets.businessinsider.comAcoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)December 13, 2024 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by BrokeragesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has been assigned an average rating of "Moderate Buy" from the fourteen ratings firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have issued a bDecember 12, 2024 | marketbeat.comFrazier Life Sciences Management L.P. Has $95.74 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Frazier Life Sciences Management L.P. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,760,457 shares of the company's stock after purchasingDecember 10, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Stock Price Up 8.4% - Should You Buy?BridgeBio Pharma (NASDAQ:BBIO) Trading 8.4% Higher - Should You Buy?December 6, 2024 | marketbeat.comPolar Asset Management Partners Inc. Buys Shares of 50,500 BridgeBio Pharma, Inc. (NASDAQ:BBIO)Polar Asset Management Partners Inc. purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,500 shares of the company's stock, valued at approximately $1,December 6, 2024 | marketbeat.comJanus Henderson Group PLC Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Janus Henderson Group PLC increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,818,012 shares of the companyDecember 5, 2024 | marketbeat.comMelqart Asset Management UK Ltd Has $10.27 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Melqart Asset Management UK Ltd increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 31.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 403,485 sharesDecember 4, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 8.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,284,802 shareDecember 4, 2024 | marketbeat.comUnnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and OncologyDecember 3, 2024 | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by HighVista Strategies LLCHighVista Strategies LLC grew its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 54.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,054 shares of the compaDecember 3, 2024 | marketbeat.comErste Asset Management GmbH Buys New Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Erste Asset Management GmbH bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 140,225 shares of the company's stock, valued at approximatelDecember 3, 2024 | marketbeat.comBiotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MoreNovember 29, 2024 | finance.yahoo.comIntech Investment Management LLC Makes New $1.14 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Intech Investment Management LLC purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 44,623 shares of the company's stocNovember 28, 2024 | marketbeat.com Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.470.44▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼187▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Teva Pharmaceutical Industries News BeiGene News Summit Therapeutics News Genmab A/S News Viatris News Intra-Cellular Therapies News Moderna News Dr. Reddy's Laboratories News Catalent News Sarepta Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
